Nurix Therapeutics, Inc. NRIX

Rank #2352 · Nasdaq · $2.8B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

22.7

P/E

-19.3

P/B

9.16

ROE

-47.4%

Op. Margin

-201.4%

Debt Ratio

47%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -19.3x, P/B 9.16x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -47.4%. Ranks in the top 90% of the universe.

Safety ★★★★☆

Good

Debt ratio 47%. Ranks in the top 22% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★

Excellent

Revenue growth of 99.3% year over year. Ranks in the top 4% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	$0.0B	$-0.0B	$-0.0B	$-0.0B	-71.5	-145
2021	$0.0B	$-0.0B	$-0.0B	$-0.0B	-71.5	-288
2022	$0.0B	$-0.1B	$-0.1B	$0.3B	-396.3	46
2023	$0.0B	$-0.2B	$-0.2B	$0.3B	-476.0	33
2024	$0.0B	$-0.2B	$-0.2B	$0.3B	-476.0	45
2025	$0.1B	$-0.2B	$-0.1B	$0.3B	-201.4	47

← See the full screener